Related Experiment Video
Updated: Jul 3, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Insulin-like growth factor-I and complications of prematurity: a focus on bronchopulmonary dysplasia
Ettore Capoluongo1, Franco Ameglio, Cecilia Zuppi
1Laboratory of Molecular Biology, Institute of Biochemistry and Clinical Biochemistry, Catholic University, Rome, Italy. ecapoluongo@rm.unicatt.it
Insights
Low serum insulin-like growth factor-I (IGF-I) is linked to serious complications in premature newborns. Local IGF-I levels, particularly in the lungs, show different regulation compared to serum levels.
Area of Science:
- Neonatal Medicine
- Endocrinology
- Pediatric Critical Care
Background:
- Premature newborns face risks of serious complications like bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, and brain damage.
- Low serum insulin-like growth factor-I (IGF-I) levels have been associated with these adverse outcomes.
- Local IGF-I concentrations, specifically in lung epithelial lining fluid, are elevated in bronchopulmonary dysplasia, suggesting differential regulation.
Purpose of the Study:
- To review the association between serum IGF-I levels and the development of complications in premature infants.
- To highlight the discrepancy between systemic and local IGF-I regulation.
- To provide methodological guidance for IGF-I assays in this population.
Main Methods:
- Literature review focusing on studies investigating serum and local IGF-I levels in premature newborns.
- Analysis of existing data linking IGF-I concentrations to specific neonatal complications.
- Discussion of the implications of differential IGF-I regulation.
Main Results:
- Low serum IGF-I is a potential biomarker for increased risk of major neonatal morbidities.
- Local IGF-I levels, such as in lung epithelial lining fluid, can be significantly higher than systemic levels, indicating compartmentalized regulation.
- The relationship between systemic and local IGF-I requires further clarification.
Conclusions:
- Serum IGF-I levels are associated with significant complications in premature infants.
- IGF-I is regulated differently in systemic circulation versus local tissue compartments.
- Further research is needed to understand the interplay between systemic and local IGF-I and its clinical implications for managing neonatal complications.
Abstract:
At least four premature newborn complications have been reported to be associated with low serum insulin-like growth factor-I (IGF-I) levels: bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis and brain damage. Local IGF-I concentrations have only been reported for bronchopulmonary dysplasia and these findings show that lung IGF-I levels are clearly increased (epithelial lining fluid levels), emphasizing the fact that IGF-I is differently regulated in the general circulation or at local level. The present review discusses the meaning of the association between serum IGF-I amounts and development of complications in premature newborns. Finally, some methodological indications are reported regarding the IGF-I assay procedures. It is important to establish what are the possible relationships between blood levels and those of different compartments involved in the diseases.
Related Concept Videos
Breathing
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
COPD: Management Using Bronchodilators and Corticosteroids
Respiratory Syncytial Virus Disease